Home > Boards > US OTC > Medical - Equipment >

Positron Corporation (POSC)

Add POSC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/5/2021 6:04:29 PM - Followers: 166 - Board type: Free - Posts Today: 1


Symbol: OTC: POSC

Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.

Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source.  Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.

Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.

Key Business Components 
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology."  Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.

Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.

Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011).  Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).  
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging. 

Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.

The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists.  This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists.
Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.

Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.

Positron is PET.

Company Website: http://www.positron.com

Share Structure
October 2017

Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979  Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares

Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#19417   Speculating that this is start of a trend. Medtrade77 03/05/21 06:04:29 PM
#19416   Interesting there hasn't been any PR issued for zenvesting 01/21/21 02:13:06 PM
#19415   Actually it’s not my decision it comes from Medtrade77 01/02/21 11:56:00 AM
#19414   That's great news for Positron! Would you mind zenvesting 12/28/20 10:38:46 AM
#19413   We are buying an Attrius. Finally getting into Medtrade77 12/24/20 12:36:47 PM
#19412   FDA approves Bracco’s CardioGen infusion system. Very positive for Medtrade77 10/20/20 10:17:48 AM
#19411   Markets are forward looking, in the meantime, the zenvesting 10/08/20 03:15:31 PM
#19410   Make that 3 months. Post covid demand 10x. Medtrade77 10/08/20 11:18:48 AM
#19409   3 year wait, any shortcut? swampboots 10/08/20 10:49:14 AM
#19408   I agree, cardiac PET is already gaining significant zenvesting 09/19/20 12:15:04 PM
#19407   Im Long here still, been picking up shares aapples1992 09/18/20 06:52:19 PM
#19406   SNMMI and Partners Host Congressional Briefing on the zenvesting 09/18/20 11:03:04 AM
#19405   F-18 trial and approval will be a huge Medtrade77 08/07/20 09:48:58 AM
#19404   Lantheus indicates the Flurpiridaz F-18 trial timeline has zenvesting 08/04/20 05:19:47 PM
#19403   Must see TV: zenvesting 06/20/20 11:15:53 AM
#19402   Avid’s F-18 marker approved for Alzheimer disease studies Medtrade77 06/17/20 09:21:54 AM
#19401   There has been some movement on the engine taxibabe 05/23/20 05:26:19 PM
#19400   Nice to see interest in Positron. The value Medtrade77 05/22/20 10:53:31 AM
#19399   March 24, 2020 Dear Positron Shareholders, On behalf of our Jackers1 04/30/20 02:06:27 PM
#19398   Someone must understand there is a hidden Medtrade77 04/29/20 07:55:49 PM
#19397   Cardiology on the front line. “Heart conditions accentuated in Medtrade77 04/23/20 12:10:07 PM
#19396   It had a false break-out to 1 dollar taxibabe 04/21/20 02:47:15 AM
#19395   Correct. $600,000 per scanner is a fair price Medtrade77 04/20/20 06:40:13 PM
#19394   Positron has been dark to the market since zenvesting 04/20/20 03:11:03 PM
#19393   Yes its interesting but the whole company is taxibabe 04/20/20 01:13:40 PM
#19392   This article explains the opportunity Positron has ahead zenvesting 04/10/20 12:33:32 AM
#19391   Positron’s scanner is best utilized for cardiac imaging. Medtrade77 04/09/20 05:38:30 PM
#19390   Can Pet Scanners be used instead of CT taxibabe 04/09/20 12:51:05 PM
#19389   Nice to see a true market forming here. Medtrade77 04/08/20 04:20:23 PM
#19388   One hundred and fifty billion dollars put aside taxibabe 03/29/20 07:04:36 PM
#19387   I sort of see that as a kind taxibabe 03/28/20 07:20:22 PM
#19386   For all who follow Positron Corporation: Today Positron put Jackers1 03/26/20 05:04:35 PM
#19385   This is true. Economics may play the most Medtrade77 03/26/20 02:22:21 PM
#19384   I agree the PET scan can be used taxibabe 03/26/20 01:09:35 PM
#19383   Healthcare will be the one industry that benefits Medtrade77 03/25/20 10:51:40 AM
#19382   Interesting someone is buying at the ask here. eom. zenvesting 03/20/20 01:59:19 PM
#19381   PET volume growing at steady pace. https://www.auntminnie.com/index.aspx?sec=lo Medtrade77 03/16/20 12:37:37 PM
#19380   I see I googled Positron Dynamics which comes taxibabe 03/05/20 12:50:52 PM
#19379   Dark stocks are difficult to research, if you zenvesting 03/05/20 11:54:10 AM
#19378   There is nothing in the article that suggests taxibabe 03/05/20 05:30:50 AM
#19377   taxibabe, it seems you overthought this and missed zenvesting 03/03/20 12:50:30 PM
#19376   I thought POSC was purely based around the taxibabe 02/29/20 12:01:02 PM
#19375   Well said. I have also heard from few Medtrade77 02/25/20 10:57:14 AM
#19374   What industry news are you referring to? zenvesting 02/24/20 05:13:19 PM
#19373   Industry keeps coming out with good news. We Medtrade77 02/24/20 02:29:36 PM
#19372   Most importantly for me will be sales Medtrade77 01/03/20 09:55:08 AM
#19371   There's a lot of tough history here for zenvesting 01/02/20 02:15:23 PM
#19370   PET was dead in water until now. I Medtrade77 01/02/20 01:02:31 PM
#19369   IMO addressing pharma was smart. No sales of Medtrade77 01/02/20 01:01:17 PM
#19368   Love is a strong word. I swallowed plinter1 01/02/20 10:23:13 AM
Consent Preferences